NASDAQ: ATRA
⬡ Derivative
Healthcare

Atara Biotherapeutics, Inc.
Shareholder Derivative Investigation

Relevant Purchase Date: Before May 20, 2024
Investigation opened October 28, 2026
Shareholders must continue to hold their shares to participate.

Follow our WhatsApp channel

About This Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Atara Biotherapeutics, Inc. (“Atara” or “the Company”) (NASDAQ: ATRA). Investors who purchased Atara securities prior to May 20, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation.

What We Are Investigating

  • 1Whether the Company's officers and directors breached their fiduciary duties to shareholders
  • 2Whether defendants caused the Company to make materially false or misleading statements
  • 3Whether defendants engaged in corporate mismanagement or waste
  • 4Whether shareholders can recover damages on behalf of the Company

Who Can Participate in the Atara Biotherapeutics, Inc. (ATRA) Derivative Action?

You may have standing to participate in this derivative action if:

  • You purchased shares of ATRA before May 20, 2024
  • You continue to hold those shares today
Important: Do not sell your ATRA shares if you want to preserve your right to participate. Derivative standing generally requires continuous ownership.

What Is a Shareholder Derivative Action?

In a shareholder derivative lawsuit, a shareholder sues on behalf of the company — not for personal damages, but to recover for harm done to the company by its own officers and directors. Any monetary recovery flows back to the company.

To bring a derivative action, a shareholder must have owned stock at the time of the alleged misconduct and must continue to hold those shares throughout the litigation. There is no class period or lead plaintiff deadline — participation is based on continuous ownership.

Derivative Action
Securities Class Action
Who it’s brought for
The company
Investors who lost money
Where recovery goes
Back to the company
To class members
Do you need to keep your shares?
Yes
No
Lead plaintiff deadline
None
Yes, usually 60 days after notice

How Is Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stock Trading Today?

Interactive chart showing the weekly share price history of NASDAQ:ATRA (NASDAQ:ATRA).

What Happens After You Contact Us?

1

Tell us about your holdings

Takes about a minute. Tell us when you bought and whether you still hold your shares.

2

We confirm your eligibility

We review whether your holdings meet the ownership requirements, at no cost or obligation.

3

We keep you updated

If a demand or lawsuit is filed, we'll contact you about your options.

Submitting information does not create an attorney-client relationship. Our firm works on a contingency fee basis.

How Does BG&G Help Investors in Shareholder Derivative Actions?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

We handle derivative actions on a contingency fee basis — we advance all litigation costs on your behalf. There is no fee unless we are successful.

"When those entrusted to run a public company abuse that trust — through self-dealing, excessive compensation, or deliberate oversight failures — shareholders have both the right and the means to hold them accountable."
— Yael Nathanson, Of Counsel

Frequently Asked Questions

Is this a class action?

No. A shareholder derivative action is brought on behalf of Atara Biotherapeutics, Inc. itself against officers or directors whose conduct may have harmed the company. It is different from a securities class action, which seeks to recover investors' own losses.

Who receives any recovery?

In a derivative action, any monetary recovery generally goes to the company, not to individual shareholders. Cases often also result in corporate governance reforms intended to benefit the company and its shareholders.

Do I need to keep my ATRA shares?

Generally, yes. To have standing in a derivative action, a shareholder typically must have owned shares at the time of the alleged misconduct and continue to hold them throughout the case.

I sold my ATRA shares. Can I still participate?

If you no longer hold your shares, you generally cannot serve as a plaintiff in a derivative action. Contact us anyway; you may have other options, including a securities class action if one is filed.

Does it cost anything?

No. Our firm works on a contingency fee basis, and there is no cost or obligation to contact us.

What documents should I have ready?

Brokerage statements showing when you purchased your ATRA shares and that you continue to hold them.

Investor Guides

Practice AreaHow Shareholder Derivative Actions WorkHow shareholders hold directors and officers accountable on behalf of the company.Learn More →

Relevant Purchase Date

Before May 20, 2024

You must continue to hold shares to participate. There is no lead plaintiff deadline for derivative actions.

Case Team

Your Contacts

Peretz Bronstein - Attorney at Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein

Founding Partner

View full bio
Nathan Miller, Head of Intake and Client Services at Bronstein, Gewirtz & Grossman, LLC

Nathan Miller

Head of Intake &
Client Services

View full bio
Call 917-590-0911 Get a Free Evaluation [email protected]

Case Details

TickerNASDAQ: ATRA
CompanyAtara Biotherapeutics, Inc.
Action TypeShareholder Derivative Investigation
Relevant Purchase DateBefore May 20, 2024
StatusUnder Investigation
Contact

Peretz Bronstein, Esq. or Nathan Miller
917-590-0911
[email protected]

Last updated: October 28, 2026

Get a Free Evaluation

If you purchased ATRA shares before May 20, 2024 and still hold them, contact us today for a free, confidential consultation.

Step 1 of 2

Join This Case

+1

Your information is kept strictly confidential. View our Privacy Policy.

Stay Informed

Get case alerts

New filings, lead plaintiff deadline reminders, and settlement notices sent to your phone.

or
Get our monthly newsletter by email →
Follow BG&G

Free. Unsubscribe anytime.